Venue | Kisaco Research

Venue

Microbiome Connect
20-21 November, 2024
Aloft Boston Seaport District Hotel

Venue

Aloft Boston Seaport District Hotel, 401-403 D Street, Boston, Massachusetts, USA, 02210

Microbiome Connect invites you to join us at the Aloft Boston Seaport District Hotel, November 20-21.

For local hotels please click here.

Microbiome Investors

Microbiome Pharma Logo Cloud

Our Trailblazing Speakers

  • Author:

    Daniel Cuoto

    Chief Operating Officer
    Vedanta Bio

    Daniel Cuoto

    Chief Operating Officer
    Vedanta Bio
  • Author:

    Nikole Kimes

    Chief Executive Officer
    Siolta Therapeutics

    Nikole Kimes

    Chief Executive Officer
    Siolta Therapeutics
  • Author:

    Bharat Dixit

    Chief Technology Officer
    Adiso Therapeutics

    Bharat Dixit

    Chief Technology Officer
    Adiso Therapeutics
  • Author:

    Cheri Ackerman

    Co-Founder & CEO
    Concerto Biosciences

    Cheri Ackerman

    Co-Founder & CEO
    Concerto Biosciences
  • Author:

    Benjamin Hadida

    Chief Executive Officer
    Exeliom Biosciences

    Benjamin Hadida

    Chief Executive Officer
    Exeliom Biosciences
  • Author:

    Mary Poor

    Vice President of Quality and CMC
    Siolta Therapeutics

    Mary Poor

    Vice President of Quality and CMC
    Siolta Therapeutics
  • Author:

    Nik Sharma

    Chief Executive Officer
    BioCortex

    Nik Sharma

    Chief Executive Officer
    BioCortex
  • Author:

    Vivek Lal

    Chief Scientific Officer
    Alveolus Bio

    Vivek Lal

    Chief Scientific Officer
    Alveolus Bio
  • Author:

    Yongkyu Kim

    CEO
    BiomATZ

    Yongkyu Kim

    CEO
    BiomATZ
  • Author:

    Tomas De Wouters

    CEO
    PharmaBiome

    Tomas De Wouters

    CEO
    PharmaBiome
  • Author:

    Matthew Cheng

    CEO
    KanvasBio

    Matthew Cheng

    CEO
    KanvasBio
  • Author:

    Travis Whitfill

    Co-Founder and Chief Scientific Officer
    Azitra

    Travis Whitfill is an Associate Research Scientist in the Department of Pediatrics. His background began in molecular biology and biochemistry, after receiving scientific training at the MD Anderson Cancer Center and Duke University. He is the co-founder of several additional startup companies, including a Connecticut-based microbiome company, Azitra Inc. He brings strong background in entrepreneurship and business, and is also a partner in a venture capital fund, Bios Partners, bringing experience in public markets, drug development, and venture capital investments.

    His research interests are in pediatric emergency medicine and health policy and to improve pediatric acute care across the United States. 

    Travis Whitfill

    Co-Founder and Chief Scientific Officer
    Azitra

    Travis Whitfill is an Associate Research Scientist in the Department of Pediatrics. His background began in molecular biology and biochemistry, after receiving scientific training at the MD Anderson Cancer Center and Duke University. He is the co-founder of several additional startup companies, including a Connecticut-based microbiome company, Azitra Inc. He brings strong background in entrepreneurship and business, and is also a partner in a venture capital fund, Bios Partners, bringing experience in public markets, drug development, and venture capital investments.

    His research interests are in pediatric emergency medicine and health policy and to improve pediatric acute care across the United States. 

  • Author:

    Christian Freguia

    Vice President of Research
    Rise Therapeutics

    Christian Freguia

    Vice President of Research
    Rise Therapeutics
  • Author:

    Sanjay Jain

    Vice President of Development
    Dermbiont

    Sanjay Jain

    Vice President of Development
    Dermbiont
  • Author:

    Jason Goldsmith

    Senior Director of Medical and Analytical Science
    Seres

    Jason Goldsmith

    Senior Director of Medical and Analytical Science
    Seres
  • Author:

    Claudio Cantabrana

    Co-founder and CEO
    Microviable Therapeutics

    Claudio Cantabrana

    Co-founder and CEO
    Microviable Therapeutics
  • Author:

    Ricardo Valladares

    CSO
    Siolta Therapeutics

    Ricardo Valladares

    CSO
    Siolta Therapeutics
  • Author:

    Mallory Gandhi

    CTO
    Hollison

    Mallory Gandhi

    CTO
    Hollison
  • Author:

    Paul Carlson

    Principal Investigator
    FDA

    Paul Carlson

    Principal Investigator
    FDA
  • Author:

    Alicia Sztretta

    Senior Director CMC
    Vedanta Bio

    Alicia Sztretta

    Senior Director CMC
    Vedanta Bio
  • Author:

    Amanda Bukardt

    Chief Executive Officer
    Phiogen

    Amanda Bukardt

    Chief Executive Officer
    Phiogen
  • Author:

    Chrysi Sergaki

    Microbiome Group Leader
    MHRA

    Chrysi Sergaki

    Microbiome Group Leader
    MHRA
  • Author:

    Jeff Heiser

    Chief Scientific Officer, Microbial & Advanced Therapeutic Platforms
    BA Sciences

    Jeff Heiser

    Chief Scientific Officer, Microbial & Advanced Therapeutic Platforms
    BA Sciences
  • Author:

    Sanjay Jain

    Vice President of Development
    Dermbiont

    Sanjay Jain

    Vice President of Development
    Dermbiont
  • Author:

    Tomas De Wouters

    CEO
    PharmaBiome

    Tomas De Wouters

    CEO
    PharmaBiome
  • Author:

    Denise Kelly

    Consultant
    Seventure

    Denise Kelly

    Consultant
    Seventure
  • Author:

    Elran Haber, PhD

    Chief Executive Officer
    Biomica

    Elran Haber, PhD

    Chief Executive Officer
    Biomica
  • Author:

    Chris Johnson

    Director of Manufacturing
    AOBiome

    Chris Johnson

    Director of Manufacturing
    AOBiome
  • Author:

    Rosa Del Campo

    Research head - Hospital Romon y Cajal
    Government of Spain Advisor

    Rosa Del Campo

    Research head - Hospital Romon y Cajal
    Government of Spain Advisor
  • Author:

    Dylan Lawrence

    Senior Scientist
    Pfizer

    Dylan Lawrence

    Senior Scientist
    Pfizer
  • Author:

    John Deaton

    Vice President
    R&D ADM

    John Deaton

    Vice President
    R&D ADM

Commercial, Collaboration and Investment Speakers

 

Moreno Perugini

President Pharma
Nestle Health Sciences

Moreno Perugini

President Pharma
Nestle Health Sciences

Moreno Perugini

President Pharma
Nestle Health Sciences
 

Daniel Cuoto

Chief Operating Officer
Vedanta Bio

Daniel Cuoto

Chief Operating Officer
Vedanta Bio

Daniel Cuoto

Chief Operating Officer
Vedanta Bio
 

Elran Haber, PhD

Chief Executive Officer
Biomica

Elran Haber, PhD

Chief Executive Officer
Biomica

Elran Haber, PhD

Chief Executive Officer
Biomica
 

Jacquelin Gaulin

Founder
Gastro Girl Inc. and Host of Gastro Girl Podcast

Jacquelin Gaulin

Founder
Gastro Girl Inc. and Host of Gastro Girl Podcast

Jacquelin Gaulin

Founder
Gastro Girl Inc. and Host of Gastro Girl Podcast
 

Paul Moayyedi

Professor, Medicine
McMaster University

Paul Moayyedi

Professor, Medicine
McMaster University

Paul Moayyedi

Professor, Medicine
McMaster University

Therapeutic and R&D Speakers

 

Nikole Kimes

Chief Executive Officer
Siolta Therapeutics

Nikole Kimes

Chief Executive Officer
Siolta Therapeutics

Nikole Kimes

Chief Executive Officer
Siolta Therapeutics
 

Benjamin Hadida

Chief Executive Officer
Exeliom Biosciences

Benjamin Hadida

Chief Executive Officer
Exeliom Biosciences

Benjamin Hadida

Chief Executive Officer
Exeliom Biosciences
 

Peter Nara

CSO
Keystone Bio Inc.

Dr. Nara is currently on of the co-founders, the Chief Scientific Officer and President Business Development for Keystone Bio Inc. in St. Louis, Mo., a Systemic-Oral Health Biomedical company that is targeting precision microbiome bio-therapeutics for the elimination of a specific oral bacterial associated with systemic inflammation. He is also the former co-founder, President, Chairman and CEO (1997-2017)and now Chairman Emeritus at Biological Mimetics, Inc. and cofounder of Lantern Pharma Inc. He holds a M.Sc. in Immuno-pharmacology, a combined Doctor of Veterinary Medicine and Ph.D.

Peter Nara

CSO
Keystone Bio Inc.

Peter Nara

CSO
Keystone Bio Inc.

Dr. Nara is currently on of the co-founders, the Chief Scientific Officer and President Business Development for Keystone Bio Inc. in St. Louis, Mo., a Systemic-Oral Health Biomedical company that is targeting precision microbiome bio-therapeutics for the elimination of a specific oral bacterial associated with systemic inflammation. He is also the former co-founder, President, Chairman and CEO (1997-2017)and now Chairman Emeritus at Biological Mimetics, Inc. and cofounder of Lantern Pharma Inc. He holds a M.Sc. in Immuno-pharmacology, a combined Doctor of Veterinary Medicine and Ph.D. (retro-virology/oncogenesis) from The Ohio State University, 4 year combined residency in Comparative Pathology and NIH post-doctoral Fellowship at the Armed Forces Institute of Pathology and a NIH respectively. Dr. Nara currently holds the Endowed Eugene Lloyd Chair, Professor in Vaccinology, founding Center Director for the Center for Advanced Host Defense, Immunobiotics, and Translational Comparative Medicine in the Department of Biomedical Sciences, in the College of Veterinary Medicine at Iowa State University and also the Chief Executive Officer, President, Chairman & co-founder of Biological Mimetics, Inc.,. He is also an distinguished Alumni of The Ohio State University College of Veterinary Medicine 2014, and an elected Fellow of the American Association for the Advancement of Science in 2011. His comparative medical research interests are to more fully understand how early and pre-determined events in the host innate and acquired immune systems are sculpted and bias the development of protective long lasting responses against infectious pathogens and cancer. More importantly  he and his team are interested developing new technologies and strategies to circumvent the non-protective immune responses for the development of novel classes of immunobiotics and vaccines focused on the prevention of disease and are translating these into viably products via a new academic- private-commercial model. He has been and continues as National and International member of numerous programs at the National Academy of Science, Institutes of Medicine, National Institutes of Health, Department of Defense, and Centers for Disease Control AIDS, World Health Organization, United Nations Global AIDS Characterization program–related and infectious diseases national planning, human and animal agricultural biodefense, vaccine development & policy reporting meetings involving pathogenesis, vaccine discovery, standardization, correlates of protection committees and consults and serves on numerous scientific advisory boards of corporate, private foundations and academic initiatives in the area of national biodefense, comparative medicine and immunology, vaccine discovery and immuno-therapeutics and a recent member of the U.S. State Department Bio-Industry Initiative Program, The Civilian Research and Development Foundation (CDRF) and The International Science and Technology Center (ISTC) for non-proliferation of biological agents.

 

Lital Gilad-Shaoulian

Chief Executive Officer
PurposeBio

Lital Gilad-Shaoulian

Chief Executive Officer
PurposeBio

Lital Gilad-Shaoulian

Chief Executive Officer
PurposeBio
 

Cheri Ackerman

Co-Founder & CEO
Concerto Biosciences

Cheri Ackerman

Co-Founder & CEO
Concerto Biosciences

Cheri Ackerman

Co-Founder & CEO
Concerto Biosciences

Data Strategy Speakers

 

Oliver Weisser

Director, Commercial Operations
Ginkgo Bioworks

Oliver Weisser

Director, Commercial Operations
Ginkgo Bioworks

Oliver Weisser

Director, Commercial Operations
Ginkgo Bioworks